Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial

DANIELA TOMASONI, B. E.T.H. DAVISON, MARIANNA ADAMO, MATTEO PAGNESI, ALEXANDRE MEBAZAA, CHRISTOPHER EDWARDS, MATTIA ARRIGO, MARIANELA BARROS, J. A.N. BIEGUS, JELENA ČELUTKIENĖ, KAMILĖ A.M.I.L. ČERLINSKAITĖ-BAJORĖ, OVIDIU CHIONCEL, ALAIN COHEN-SOLAL, ALBERTINO DAMASCENO, RAFAEL DIAZ, GERASIMOS FILIPPATOS, ETIENNE GAYAT, ANTOINE KIMMOUN, CAROLYN S.P. LAM, MARIA NOVOSADOVAPETER S. PANG, PIOTR PONIKOWSKI, HADIZA SAIDU, KAREN SLIWA, K. O.J.I. TAKAGI, JOZINE M.TER MAATEN, ADRIAAN VOORS, G. A.D. COTTER, MARCO METRA*

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

9 Citaten (Scopus)
2 Downloads (Pure)

Samenvatting

Background: Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies (STRONG-HF) demonstrated the safety and efficacy of rapid up-titration of guideline-directed medical therapy (GDMT) with high-intensity care (HIC) compared with usual care in patients hospitalized for acute heart failure (HF). In the HIC group, the following safety indicators were used to guide up-titration: estimated glomerular filtration rate of <30 mL/min/1.73 m2, serum potassium of >5.0 mmol/L, systolic blood pressure (SBP) of <95 mmHg, heart rate of <55 bpm, and N-terminal pro-B-type natriuretic peptide concentration of >10% higher than predischarge values. 

Methods and Results: We examined the impact of protocol-specified safety indicators on achieved dose of GDMT and clinical outcomes. Three hundred thirteen of the 542 patients in the HIC arm (57.7%) met ≥1 safety indicator at any follow-up visit 1–6 weeks after discharge. As compared with those without, patients meeting ≥1 safety indicator had more severe HF symptoms, lower SBP, and higher heart rate at baseline and achieved a lower average percentage of GDMT optimal doses (mean difference vs the HIC arm patients not reaching any safety indicator, –11.0% [95% confidence interval [CI] –13.6 to –8.4%], P < .001). The primary end point of 180-day all-cause death or HF readmission occurred in 15.0% of patients with any safety indicator vs 14.2% of those without (adjusted hazard ratio 0.84, 95% CI 0.48–1.46, P = .540). None of each of the safety indicators, considered alone, was significantly associated with the primary end point, but an SBP of <95 mm Hg was associated with a trend toward increased 180-day all-cause mortality (adjusted hazard ratio 2.68, 95% CI 0.94–7.64, P = .065) and estimated glomerular filtration rate decreased to <30 mL/min/1.73 m2 with more HF readmissions (adjusted hazard ratio 3.60, 95% CI 1.22–10.60, P = .0203). The occurrence of a safety indicator was associated with a smaller 90-day improvement in the EURO-QoL 5-Dimension visual analog scale (adjusted mean difference –3.32 points, 95% CI –5.97 to –0.66, P = .015). 

Conclusions: Among patients with acute HF enrolled in STRONG-HF in the HIC arm, the occurrence of any safety indicator was associated with the administration of slightly lower GDMT doses and less improvement in quality of life, but with no significant increase in the primary outcome of 180-day HF readmission or death when appropriately addressed according to the study protocol.

Originele taal-2English
Pagina's (van-tot)525-537
Aantal pagina's13
TijdschriftJournal of Cardiac Failure
Volume30
Nummer van het tijdschrift4
Vroegere onlinedatum9-okt.-2023
DOI's
StatusPublished - apr.-2024

Vingerafdruk

Duik in de onderzoeksthema's van 'Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial'. Samen vormen ze een unieke vingerafdruk.

Citeer dit